Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Radwa M Fawzy, Amal A Abdel-Aziz, Khalid Bassiouny, Aysam M Fayed
BACKGROUND: Breast cancer (BC) has transcended lung cancer as the most common cancer in the world. Due to the disease's aggressiveness, rapid growth, and heterogeneity, it is crucial to investigate different therapeutic approaches for treatment. According to the World Health Organization (WHO), Plant-based therapeutics continue to be utilized as safe/non-toxic complementary or alternative treatments for cancer, even in developed countries, regardless of how cutting-edge conventional therapies are...
March 2024: Journal, Genetic Engineering & Biotechnology
#2
JOURNAL ARTICLE
James Yarmolinsky, Jamie W Robinson, Daniela Mariosa, Ville Karhunen, Jian Huang, Niki Dimou, Neil Murphy, Kimberley Burrows, Emmanouil Bouras, Karl Smith-Byrne, Sarah J Lewis, Tessel E Galesloot, Lambertus A Kiemeney, Sita Vermeulen, Paul Martin, Demetrius Albanes, Lifang Hou, Polly A Newcomb, Emily White, Alicja Wolk, Anna H Wu, Loïc Le Marchand, Amanda I Phipps, Daniel D Buchanan, Sizheng Steven Zhao, Dipender Gill, Stephen J Chanock, Mark P Purdue, George Davey Smith, Paul Brennan, Karl-Heinz Herzig, Marjo-Riitta Järvelin, Chris I Amos, Rayjean J Hung, Abbas Dehghan, Mattias Johansson, Marc J Gunter, Kostas K Tsilidis, Richard M Martin
BACKGROUND: Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. METHODS: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry...
February 2024: EBioMedicine
#3
JOURNAL ARTICLE
Seyed Vahid Jasemi, Soha Zia, Seyed Ghasem Mirbahari, Masoud Sadeghi
INTRODUCTION: The exact mechanism responsible for inflammation in malignancy is not completely understood, but it is possible that interleukin-6 (IL-6) plays a major role in triggering and maintaining an inflammatory response. AIM: To conduct a systematic review and meta-analysis of the levels of IL-6 in the serum/plasma of lung cancer (LC) patients. MATERIAL AND METHODS: The researchers searched four databases up to September 11, 2022, to find studies that reported on IL-6 levels in LC patients compared to healthy controls (HCs)...
December 2023: Polish Journal of Cardio-Thoracic Surgery
#4
JOURNAL ARTICLE
Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Shuo Liu, Mengjun Hou, Yaling Long, Xuansheng Ding
CONTEXT: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injection (SFI) is widely accepted as an adjuvant therapy in NSCLC. OBJECTIVE: This study investigates the molecular mechanism of SFI when combined with gefitinib in regulating cell progression among EGFR-TKI-resistant NSCLC. MATERIALS AND METHODS: We established gefitinib-resistant PC9-GR cells by exposing gefitinib escalation from 10 nM with the indicated concentrations of SFI in PC9 cells (1, 4, and 8 mg/mL)...
December 2024: Pharmaceutical Biology
#5
JOURNAL ARTICLE
Tamar Ben-Mordechai, Yaacov R Lawrence, Zvi Symon, Ariel Shimoni-Sebag, Uri Amit
INTRODUCTION: Chemokine (C-X3-C Motif) Receptor 1 (CX3CR1) is present in a subset of the immune cells in the tumor microenvironment (TME) and plays an essential and diverse role in cancer progression. However, its potential function in the irradiated TME remains unknown. MATERIALS AND METHODS: A mouse lung cancer model was performed by subcutaneously inoculating Lewis Lung Carcinoma (LLC) cells expressing luciferase (Luc-2) and mCherry cells in CX3CR1GFP/GFP , CX3CR1DTR/+ , and wild-type (WT) mice...
November 19, 2023: Cancers
#6
REVIEW
Freddy Elad Essogmo, Angelina V Zhilenkova, Yvan Sinclair Ngaha Tchawe, Abah Moses Owoicho, Alexander S Rusanov, Alexander Boroda, Yuliya N Pirogova, Zaiana D Sangadzhieva, Varvara D Sanikovich, Nikolay N Bagmet, Marina I Sekacheva
Lung cancer is currently the second leading cause of cancer death worldwide. In recent years, checkpoint inhibitor immunotherapy (ICI) has emerged as a new treatment. A better understanding of the tumor microenvironment (TMJ) or the immune system surrounding the tumor is needed. Cytokines are small proteins that carry messages between cells and are known to play an important role in the body's response to inflammation and infection. Cytokines are important for immunity in lung cancer. They promote tumor growth (oncogenic cytokines) or inhibit tumor growth (anti-tumour cytokines) by controlling signaling pathways for growth, proliferation, metastasis, and apoptosis...
November 13, 2023: Cancers
#7
JOURNAL ARTICLE
Long Gui, Mingjin Cheng, Min Zheng, Chengdong Ning, Qianlun Huo
BACKGROUND: The primary objective of this study was to investigate the effects of oral omega-3 fatty acids in lowering the risk of malnutrition and improving the inflammatory response in patients with stage II-III lung cancer receiving postoperative chemotherapy. METHODS: One hundred and three lung cancer patients identified as being at risk for malnutrition according to the 2002 nutritional risk screening criteria were randomized into either the omega-3 fatty acid supplementation group or the placebo group during postoperative chemotherapy...
2023: Frontiers in Nutrition
#8
JOURNAL ARTICLE
Chunhai Li, Lixin Wang, Daqian Sun, Tianxiao Yao, Xiuying Xian, Yufeng Cheng
AIMS: To explore the occurrence and possible mechanism of colitis in Lewis mice treated with PD-1 inhibitor combined with platinum-containing dual drug chemotherapy. SUBJECTS AND METHODS: A Lewis lung cancer model of C57BL/6 mice was established, randomly divided into the treatment group (group C, PD-1 inhibitor + Carboplatin (CARB) + Pemetrexed (PEM)) and model group (group B, normal saline), and a control group (group A, normal saline) was set up. Observe the changes in tumor-free weight, tumor volume, disease activity index (DAI), colon histopathology, identify serum interleukin (IL)-10, interferon (IFN)-γ, the expression of claudin-1, and occludin mRNA in the colon in each animals...
August 2023: Journal of Cancer Research and Therapeutics
#9
JOURNAL ARTICLE
Rena Pollack, Joshua Stokar, Natan Lishinsky, Irina Gurt, Naomi Kaisar-Iluz, Merav E Shaul, Zvi G Fridlender, Rivka Dresner-Pollak
Immune checkpoint inhibitors (ICI) are commonly associated with thyroid immune-related adverse events, yet the mechanism has not been fully elucidated. We aimed to further explore the mechanism of ICI-induced thyroid dysfunction by assessing changes induced in the thyroid transcriptome by ICI treatment (αPD-1/αPD-L1) in a lung cancer murine model. RNA-sequencing of thyroid tissues revealed 952 differentially expressed genes (DEGs) with αPD-1 treatment (|fold-change| ≥1.8, FDR < 0...
June 23, 2023: International Journal of Molecular Sciences
#10
JOURNAL ARTICLE
Anastasios D Giannou, Jan Kempski, Tao Zhang, Jöran Lücke, Ahmad Mustafa Shiri, Dimitra E Zazara, Ioannis Belios, Andres Machicote, Philipp Seeger, Theodora Agalioti, Joseph Tintelnot, Adrian Sagebiel, Miriam Tomczak, Lennart Bauditz, Tanja Bedke, Lorenz Kocheise, Baris Mercanoglu, Mohammad Fard-Aghaie, Emmanouil Giorgakis, Panagis M Lykoudis, Anastasia Pikouli, Julia-Kristin Grass, Ramez Wahib, Jan Bardenhagen, Benjamin Brunswig, Asmus Heumann, Tarik Ghadban, Anna Duprée, Michael Tachezy, Nathaniel Melling, Petra C Arck, Pablo Stringa, Maria Virginia Gentilini, Gabriel E Gondolesi, Ryosuke Nakano, Angus W Thomson, Daniel Perez, Jun Li, Oliver Mann, Jakob R Izbicki, Nicola Gagliani, Ioannis C Maroulis, Samuel Huber
BACKGROUND: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown. METHODS: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells...
2023: Frontiers in Oncology
#11
JOURNAL ARTICLE
Xiang Zheng, Poonam Sarode, Andreas Weigert, Kati Turkowski, Prakash Chelladurai, Stefan Günther, Carsten Kuenne, Hauke Winter, Albrecht Stenzinger, Simone Reu, Friedrich Grimminger, Thorsten Stiewe, Werner Seeger, Soni Savai Pullamsetti, Rajkumar Savai
UNLABELLED: Tumor-associated macrophages (TAM), including antitumor M1-like TAMs and protumor M2-like TAMs, are transcriptionally dynamic innate immune cells with diverse roles in lung cancer development. Epigenetic regulators are key in controlling macrophage fate in the heterogeneous tumor microenvironment. Here, we demonstrate that the spatial proximity of HDAC2-overexpressing M2-like TAMs to tumor cells significantly correlates with poor overall survival of lung cancer patients. Suppression of HDAC2 in TAMs altered macrophage phenotype, migration, and signaling pathways related to interleukins, chemokines, cytokines, and T-cell activation...
July 14, 2023: Cancer Research
#12
James Yarmolinsky, Jamie W Robinson, Daniela Mariosa, Ville Karhunen, Jian Huang, Niki Dimou, Neil Murphy, Kimberley Burrows, Emmanouil Bouras, Karl Smith-Byrne, Sarah J Lewis, Tessel E Galesloot, Lambertus A Kiemeney, Sita Vermeulen, Paul Martin, Demetrius Albanes, Lifang Hou, Polly A Newcomb, Emily White, Alicja Wolk, Anna H Wu, Loïc Le Marchand, Amanda I Phipps, Daniel D Buchanan, Sizheng Steven Zhao, Dipender Gill, Stephen J Chanock, Mark P Purdue, George Davey Smith, Paul Brennan, Karl-Heinz Herzig, Marjo-Riitta Jarvelin, Abbas Dehghan, Mattias Johansson, Marc J Gunter, Kostas K Tsilidis, Richard M Martin
BACKGROUND: Tumour-promoting inflammation is a "hallmark" of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. METHODS: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry...
May 5, 2023: medRxiv
#13
JOURNAL ARTICLE
Jing Pan, Jun Xing, Haiyang Yu, Ziming Wang, Wei Wang, Yueyin Pan
BACKGROUND: It has been shown that circular RNAs (circRNAs) are involved in the pathogenesis of non-small cell lung cancer (NSCLC). However, the molecular mechanisms of circRNAs in tumor malignant progression and tyrosine kinase inhibitors (TKI) resistance remain undefined. Hereby, we explored the mechanisms by which circRBM33 promotes NSCLC progression and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) resistance. METHODS: Transcriptome sequencing (RNA-seq) was carried out to obtain the circRBM33 we investigated...
March 31, 2023: Annals of Translational Medicine
#14
JOURNAL ARTICLE
Zhuang Tong, Xu Wang, Hongyu Liu, Jian Ding, Yinling Chu, Xin Zhou
BACKGROUND: To depict the immune infiltration characteristics of tumor cells in patients with lung adenocarcinoma (LUAD) and evaluate the predictive value and significance of tumor immune cells on the prognosis of LUAD patients. METHODS: The clinical characteristics and transcriptome of LUAD patients were obtained from The Cancer Genome Atlas (TCGA), and the immune cell abundance in LUAD tissue was evaluated using the CIBERSORT algorithm. We created a simplified immune cell-based Cox regression model according to the survival status of patients and clarified the correlation between the survival status of patients and seven types of immune cells...
February 28, 2023: Journal of Thoracic Disease
#15
JOURNAL ARTICLE
Pochung Jordan Chou, Md Shahid Sarwar, Lujing Wang, Renyi Wu, Shanyi Li, Rasika R Hudlikar, Yujue Wang, Xiaoyang Su, Ah-Ng Kong
UNLABELLED: Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase (HDAC) inhibitor with anticancer effects via epigenetic and non-epigenetic mechanisms. The role of SAHA in metabolic rewiring and epigenomic reprogramming to inhibit pro-tumorigenic cascades in lung cancer remains unknown. In this study, we aimed to investigate the regulation of mitochondrial metabolism, DNA methylome reprogramming, and transcriptomic gene expression by SAHA in lipopolysaccharide (LPS)-induced inflammatory model of lung epithelial BEAS-2B cells...
June 1, 2023: Cancer Prevention Research
#16
JOURNAL ARTICLE
Miao Zhang, Yi Sun, Yan Zhang, Zhen Wang, Zhao-Yi Wang, Xi-Yue Ming, Zhen-Dong Guo
BACKGROUND: Lung cancer (LC) is a malignancy with one of the highest mortality rates. Respiratory microbiota is considered to play a key role in the development of LC, but the molecular mechanisms are rarely studied. METHODS: We used lipopolysaccharide (LPS) and lipoteichoic acid (LTA) to study human lung cancer cell lines PC9 and H1299. The gene expression of CXC chemokine ligand (CXCL)1/6, interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-α were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR)...
January 31, 2023: Journal of Thoracic Disease
#17
JOURNAL ARTICLE
Zhi Yan, Jian-Xun Wen, Xi-Shan Cao, Wen Zhao, Yu-Ling Han, Xu-Hui Wen, Li Yan, Man Zhang, Ya-Fei Wang, Ling Hai, Ying-Jun Wang, Wen-Qi Zheng, Zhi-De Hu
BACKGROUND: Tumor-associated macrophages (TAMs) affects the outcomes of non-small cell lung cancer (NSCLC). NSCLC cells released exosomes to suppress the antitumor activity of TAMs. MiR-146a is a critical regulator in TAM polarization. We hypothesized that NSCLC cells released exosomal miR-146a to regulate TAM polarization and thus affected its antitumor activity. METHODS: We used H1299 cells-derived exosomes to stimulate THP-1 cells that was pretreated with phorbol 12-myristate 13-acetate (M0 macrophage)...
December 2022: Annals of Translational Medicine
#18
Juan Yan, Na Ma, Wei-Li Qiao, Ke-Qin Liu, Dai-Wei Liu, Yu Wang, Ting-Ting Qiao, Xiu-Qing Hao, Mao-Dong Zheng
BACKGROUND: Sintilimab is an immune checkpoint inhibitor (ICI). It can induce immune-related Adverse Events (irAEs). Severe adverse skin reactions are rare, but the mortality rate is high. We report the first case of successful treatment of adverse skin reactions using traditional Chinese medicine (TCM). CASE DESCRIPTION: Here we present the case of a 67-year-old male with advanced lung squamous carcinoma. After 8 cycles of chemotherapy, the patient's disease progressed and the treatment regimen was adjusted to sintilimab combined with albumin paclitaxel and cisplatin...
December 2022: Annals of Translational Medicine
#19
JOURNAL ARTICLE
Daria Briukhovetska, Javier Suarez-Gosalvez, Cornelia Voigt, Anamarija Markota, Anastasios D Giannou, Maryam Schübel, Jakob Jobst, Tao Zhang, Janina Dörr, Florian Märkl, Lina Majed, Philipp Jie Müller, Peter May, Adrian Gottschlich, Nicholas Tokarew, Jöran Lücke, Arman Oner, Melanie Schwerdtfeger, David Andreu-Sanz, Ruth Grünmeier, Matthias Seifert, Stefanos Michaelides, Michael Hristov, Lars M König, Bruno Loureiro Cadilha, Oleg Mikhaylov, Hans-Joachim Anders, Simon Rothenfusser, Richard A Flavell, Daniela Cerezo-Wallis, Cristina Tejedo, María S Soengas, Tobias Bald, Samuel Huber, Stefan Endres, Sebastian Kobold
Although T cells can exert potent anti-tumor immunity, a subset of T helper (Th) cells producing interleukin-22 (IL-22) in breast and lung tumors is linked to dismal patient outcome. Here, we examined the mechanisms whereby these T cells contribute to disease. In murine models of lung and breast cancer, constitutional and T cell-specific deletion of Il22 reduced metastases without affecting primary tumor growth. Deletion of the IL-22 receptor on cancer cells decreases metastasis to a degree similar to that seen in IL-22-deficient mice...
January 10, 2023: Immunity
#20
JOURNAL ARTICLE
Anastasios D Giannou, Jan Kempski, Ahmad Mustafa Shiri, Jöran Lücke, Tao Zhang, Lilan Zhao, Dimitra E Zazara, Filippo Cortesi, Kristoffer Riecken, Maria Carolina Amezcua Vesely, Jun Siong Low, Hao Xu, Eleanna Kaffe, Laura Garcia-Perez, Theodora Agalioti, Yoshito Yamada, Wolfgang Jungraithmayr, Ehud Zigmond, Karl-Frederick Karstens, Babett Steglich, Jonas Wagner, Leonie Konczalla, Antonella Carambia, Kornelius Schulze, Johann von Felden, Peter May, Daria Briukhovetska, Tanja Bedke, Leonie Brockmann, Sarah Starzonek, Tobias Lange, Claudia Koch, Sabine Riethdorf, Penelope Pelczar, Marius Böttcher, Morsal Sabihi, Francis J Huber, Matthias Reeh, Julia Kristin Grass, Ramez Wahib, Hannes Seese, Björn-Ole Stüben, Mohammad Fard-Aghaie, Anna Duprée, Pasquale Scognamiglio, Gabriel Plitzko, Jan Meiners, Shiwa Soukou, Agnes Wittek, Caroline Manthey, Ioannis C Maroulis, Petra C Arck, Daniel Perez, Bin Gao, Sotirios G Zarogiannis, Till Strowig, Renata Pasqualini, Wadih Arap, Javier Suárez Gosálvez, Sebastian Kobold, Immo Prinz, Andreas H Guse, Michael Tachezy, Tarik Ghadban, Asmus Heumann, Jun Li, Nathaniel Melling, Oliver Mann, Jakob R Izbicki, Klaus Pantel, Udo Schumacher, Ansgar W Lohse, Richard A Flavell, Nicola Gagliani, Samuel Huber
During metastasis, cancer cells invade, intravasate, enter the circulation, extravasate, and colonize target organs. Here, we examined the role of interleukin (IL)-22 in metastasis. Immune cell-derived IL-22 acts on epithelial tissues, promoting regeneration and healing upon tissue damage, but it is also associated with malignancy. Il22-deficient mice and mice treated with an IL-22 antibody were protected from colon-cancer-derived liver and lung metastasis formation, while overexpression of IL-22 promoted metastasis...
January 10, 2023: Immunity
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
